logo/base Created with Sketch.

International Clinical Practice Guidelines
Related to FibroScan®

These latest guidelines – for healthcare professionals only – define the role of diagnostic and treatment modalities in the management of patients with chronic liver disease. These recommendations are defined by internationally recognized scientific organizations and are based on the best available research data and practical experience. 


Recommendations in Hepatology & Gastroenterology 

EASL Clinical Practice Guidelines
on Non-invasive Tests for Evaluation of Liver Disease Severity and Prognosis
– 2021 Update –

These EASL guidelines are a big step towards non-invasive management of patients with liver disease.

Baveno VII
Renewing Consensus in Portal Hypertension 
– 2021 Update –

These Baveno VII guidelines applies for the management of patients with advanced chronic liver disease. 

AGA Clinical Care Pathway
for the Risk Stratification and Management
of Patients With Nonalcoholic Fatty Liver Disease 
– 2021 Update –

These AGA guidelines indicate how to determine which risk-factor patients will benefit from testing, the NIT-based FIB-4 + LSM by VCTE™ test sequence and risk-stratified disease management guidance. 

AASLD Practice Guidance
on the Clinical Assessment and Management
of Nonalcoholic Fatty Liver Disease
– 2023 Update –

The new Practice Guidance from the AASLD suggests the use of VCTE™, a patented technology used by FibroScan® solutions from Echosens, for detecting and diagnosing NAFLD in high-risk individuals, including those with type 2 diabetes (T2D).

Recommendations in Diabetology & Endocrinology

AACE Clinical Practice Guidelines
for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease
in Primary Care and Endocrinology Clinical Settings 
– 2022 Update –

These new guidelines are a breakthrough in early diagnosis and management of patients with NAFLD targeting primary care and endocrinology clinical settings. 

Recommendations in Cardiology

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk
A Scientific Statement from the American Heart Association 
– 2022 Update –

The purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.